Delamanid by Otsuka Pharmaceutical for Pulmonary Tuberculosis: Likelihood of Approval

Delamanid by Otsuka Pharmaceutical for Pulmonary Tuberculosis: Likelihood of Approval

Publication date: Jan 01, 2025

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. According to GlobalData, Phase III drugs for Pulmonary Tuberculosis have a 50% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. It is indicated for use as part of an appropriate combination regimen for pulmonary multidrug-resistant tuberculosis (MDR-TB) in adult patients It acts by targeting bacterial cell wall. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval. The drug candidate is under development for the treatment of pulmonary multidrug-resistant tuberculosis GlobalData’s report assesses how Delamanid’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Delamanid is under clinical development by Otsuka Pharmaceutical and currently in Phase III for Pulmonary Tuberculosis.

Concepts Keywords
Globaldata Approval
Historical Clinical
Pharmaceutical Delamanid
Tuberculosis Drug
Globaldata
Iii
Indication
Likelihood
Otsuka
Pharmaceutical
Phase
Ptsr
Pulmonary
Specific
Tuberculosis

Semantics

Type Source Name
drug DRUGBANK Pirenzepine
disease MESH PANIC
disease IDO object
disease IDO site
pathway KEGG Tuberculosis
disease MESH tuberculosis
drug DRUGBANK Coenzyme M
disease MESH Pulmonary Tuberculosis
drug DRUGBANK Delamanid

Leave a Comment

Your email address will not be published. Required fields are marked *